In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation

Blood

Volumn 96, Issue 7, 2000, Pages 2419-2425

  Kottaridis, P D ^a   Milligan, D W ^a   Chopra, R ^a   Chakraverty, R K ^a   Chakrabarti, S ^a   Robinson, S ^a   Peggs, K ^a   Verfuerth, S ^a   Pettengell, R ^a   Marsh, J C W ^a   Schey, S ^a   Mahendra, P ^a   Morgan, G J ^a   Hale, G ^a   Waldmann, H ^a   Carmen Ruiz de Elvira, M ^a   Williams, C D ^a   Devereux, S ^a   Linch, D C ^a   Goldstone, A H ^a   Mackinnon, S ^a   more..

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN; MELPHALAN; METHOTREXATE;

ADULT; ARTICLE; CHIMERA; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; FOLLOW UP; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HLA MATCHING; HUMAN; MALE; MORTALITY; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0034307366     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.7.2419     Document Type: Article

References (28)

1. Outcome after allogeneic bone marrow transplant for leukemia in older adults
2. Bone marrow transplantation in patients aged 45 years and older
3. Antileukemic effect of graft-versus-host disease in recipients of allogeneic marrow grafts
4. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
5. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia following bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
6. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): Evidence for a graft-versus-myeloma effect
7. Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18)
8. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
9. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
10. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
11. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses
12. Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting
13. Non myeloablative conditioning with fludarabine/melphalan (FM) for patients with multiple myeloma (MM)
14. Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation in poor candidates for conventional myeloablative conditioning
15. Reshaping human antibodies for therapy
16. 1994 Consensus Conference on Acute GVHD Grading
17. Myeloid and lymphoid chimerism following T-cell depleted bone marrow transplantation: Evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA
18. Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection
19. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease
20. Mixed chimerism after allogeneic marrow transplantation for leukaemia: Correlation with dose of total body irradiation and graft-versus-host disease
21. Use of minisatellite DNA probes for recognition and characterization of relapse after allogenic bone marrow transplantation
22. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transpantation for chronic myelogenous leukemia
23. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties
24. Mixed lymphohaemopoietic chimerism and graft-versuslymphoma effects after non-myeloablative therapy and HLA-mismatched bone marrow transplantation
25. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation
26. Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
27. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation
28. Clonable T lymphocytes in T-cell depleted bone marrow transplants correlate with development of graft-versus-host disease